RecruitingPhase 1Phase 2NCT03457493

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy


Sponsor

University of Alabama at Birmingham

Enrollment

205 participants

Start Date

Mar 22, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of \[18F\]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with \[18F\]DPA-714-PET/MRI.


Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This study is using a specialized brain scan (PET scan) to measure inflammation in the brains of people with Parkinson's disease, to better understand the role of the immune system in the disease's progression. **You may be eligible if...** - You are already enrolled in a related UAB Parkinson's Disease research study - You are 30 years of age or older - You have a specific genetic marker (called TSPO high or mixed affinity binder, determined by a simple genetic test) - Women of childbearing potential must have a negative pregnancy test **You may NOT be eligible if...** - You have a TSPO low-affinity genetic result (a specific genetic variant that makes the brain scan unreliable) - You have a condition that makes MRI or PET scanning unsafe - Your Parkinson's symptoms or other health problems prevent you from safely undergoing the imaging - You do not meet eligibility criteria for the parent UAB Parkinson's studies Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDPA-714-PET/MRI

DPA-714-PET/MRI

DRUG5-year Follow-up DPA-714-PET/MRI

PET/MRI scan with DPA-714

DRUGDPA-714 Metabolite Analysis

Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.


Locations(1)

UAB Advanced Imaging Facility

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03457493


Related Trials